[
    [
        {
            "time": "2023-10-15",
            "original_text": "Eli Lilly's Mirikizumab Beat Placebo At Controlling, Resolving Ulcerative Colitis Symptoms",
            "features": {
                "keywords": [
                    "Mirikizumab",
                    "placebo",
                    "ulcerative colitis",
                    "symptoms"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Eli Lilly's Mirikizumab Beat Placebo At Controlling, Resolving Ulcerative Colitis Symptoms",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-16",
            "original_text": "Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation",
            "features": {
                "keywords": [
                    "Lilly",
                    "Alzheimer's",
                    "drug",
                    "fails",
                    "investor expectation"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "Lilly (LLY) Down as Alzheimer's Drug Fails Investor Expectation",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-17",
            "original_text": "Dip in Eli Lilly Stock Makes It a Buy, Mizuho Analyst Says",
            "features": {
                "keywords": [
                    "dip",
                    "Eli Lilly",
                    "stock",
                    "buy",
                    "Mizuho analyst"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Dip in Eli Lilly Stock Makes It a Buy, Mizuho Analyst Says",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2023-10-18",
            "original_text": "The Zacks Analyst Blog Highlights: MGM Resorts, American Airlines, Blackstone Group, Extended Stay America and Eli Lilly",
            "features": {
                "keywords": [
                    "Zacks",
                    "analyst blog",
                    "MGM Resorts",
                    "American Airlines",
                    "Blackstone Group",
                    "Extended Stay America",
                    "Eli Lilly"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals",
                    "travel",
                    "real estate"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "The Zacks Analyst Blog Highlights: MGM Resorts, American Airlines, Blackstone Group, Extended Stay America and Eli Lilly",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 4,
                "Impact": 3,
                "Duration": 3,
                "Entity_Density": 6,
                "Market_Scope": 6,
                "Time_Proximity": 5,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        },
        {
            "time": "2023-10-19",
            "original_text": "AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail",
            "features": {
                "keywords": [
                    "AstraZeneca",
                    "U.S.",
                    "COVID-19",
                    "antibody-based cocktail",
                    "doses"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "AstraZeneca to supply U.S. with extra 500,000 doses of COVID-19 antibody-based cocktail",
                "Correlation": 2,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2023-10-20",
            "original_text": "UPDATE 1-Eli Lilly bowel disease treatment succeeds in late-stage study",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "bowel disease",
                    "treatment",
                    "late-stage study"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "UPDATE 1-Eli Lilly bowel disease treatment succeeds in late-stage study",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2023-10-21",
            "original_text": "Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study",
            "features": {
                "keywords": [
                    "Mirikizumab",
                    "clinical remission",
                    "ulcerative colitis",
                    "Phase 3 induction study"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "healthcare",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "Lilly's Mirikizumab Helps Patients Achieve Clinical Remission and Improves Symptoms in Adults with Ulcerative Colitis in 12-Week Phase 3 Induction Study",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]